Hexokinase 2 (HK2) and pyruvate kinase M2 (PKM2), the rate-limiting enzymes of cellular glycolysis, are remarkably upregulated in glioma, colorectal cancer, and liver cancer, promoting glycolysis and have been generally accepted as key factors in the reprogramming of glucose metabolism [24–26]. The gene discussed is HK2; the disease is colorectal cancer.